预约演示
更新于：2025-01-21
Moxifloxacin Hydrochloride
盐酸莫西沙星
更新于：2025-01-21
概要
基本信息
药物类型 小分子化药 |
别名 MFLX、Moxifloxacin、Moxifloxacin hydrochloride (JAN/USP) + [25] |
作用机制 细菌DNA旋转酶复合体抑制剂、拓扑异构酶 IV抑制剂 |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C21H25ClFN3O4 |
InChIKeyIDIIJJHBXUESQI-DFIJPDEKSA-N |
CAS号186826-86-8 |
关联
415
项与 盐酸莫西沙星 相关的临床试验NCT03244072
Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery
NCT06746402
A Phase 1, Two-Part, Double-blind, Placebo-controlled, Randomized Study of the Safety, Tolerability, and Pharmacokinetics of BMS-986278 (Part A) and a Randomized, Double-blind, Positive-controlled, Placebo-controlled, 4-Period Crossover, Thorough QT/QTc Study to Evaluate the Effect of Multiple Doses of BMS-986278 on Cardiac Repolarization (Part B) in Healthy Participants
NCT06253715
Shortened Regimen for Drug-susceptible TB in Children
100 项与 盐酸莫西沙星 相关的临床结果
登录后查看更多信息
100 项与 盐酸莫西沙星 相关的转化医学
登录后查看更多信息
100 项与 盐酸莫西沙星 相关的专利（医药）
登录后查看更多信息
6,341
项与 盐酸莫西沙星 相关的文献（医药）2025-12-31Gut Microbes
A modelling framework to characterize the impact of antibiotics on the gut microbiota diversity
Article
作者: de Gunzburg, Jean ; Corbel, Tanguy ; Burdet, Charles ; Ferreira, Stéphanie ; Olivares, Carlos ; Guedj, Jeremie ; Ruppé, Etienne ; Andremont, Antoine
Metagenomic sequencing deepened our knowledge about the role of the intestinal microbiota in human health, and several studies with various methodologies explored its dynamics during antibiotic treatments. We compared the impact of four widely used antibiotics on the gut bacterial diversity. We used plasma and fecal samples collected during and after treatment from healthy volunteers assigned to a 5-day treatment either by ceftriaxone (1 g every 24 h through IV route), ceftazidime/avibactam (2 g/500 mg every 8 h through IV route), piperacillin/tazobactam (1 g/500 mg every 8 h through IV route) or moxifloxacin (400 mg every 24 h through oral route). Antibiotic concentrations were measured in plasma and feces, and bacterial diversity was assessed by the Shannon index from 16S rRNA gene profiling. The relationship between the evolutions of antibiotic fecal exposure and bacterial diversity was modeled using non-linear mixed effects models. We compared the impact of antibiotics on gut microbiota diversity by simulation, using various reconstructed pharmacodynamic indices. Piperacillin/tazobactam was characterized by the highest impact in terms of intensity of perturbation (maximal [IQR] loss of diversity of 27.3% [1.9; 40.0]), while moxifloxacin had the longest duration of perturbation, with a time to return to 95% of baseline value after the last administration of 13.2 d [8.3; 19.1]. Overall, moxifloxacin exhibited the highest global impact, followed by piperacillin/tazobactam, ceftazidime/avibactam and ceftriaxone. Their AUC between day 0 and day 42 of the change of diversity indices from day 0 were, respectively, -13.2 Shannon unit.day [-20.4; -7.9], -10.9 Shannon unit.day [-20.4; -0.6] and -10.1 Shannon unit.day [-18.3; -4.6]. We conclude that antibiotics alter the intestinal diversity to varying degrees, both within and between antibiotics families. Such studies are needed to help antibiotic stewardship in using the antibiotics with the lowest impact on the intestinal microbiota.
2025-03-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Moxifloxacin-loaded PVA-chitosan composite films as potential ocular drug delivery systems: A comprehensive characterization and efficacy assessment
Article
作者: Pattnaik, Gurudutta ; Das, Swagatika ; Habibullah, Sk ; Behera, Amulyaratna ; Mohanty, Biswaranjan
To overcome the barriers often met by traditional ophthalmic formulations, polymeric films can be utilized as an alternative to enhance drug retention duration while managing medication release. In the current investigation, polymeric films made of poly (vinyl) alcohol (PVA) and chitosan (CS) loaded with Moxifloxacin Hydrochloride (M-HCl) and plasticized with Glutaraldehyde were formulated as potential ophthalmic delivery for the treatment of conjunctivitis. The thickness, surface pH, opacity, folding endurance, and % hemolysis were measured, followed by the transparency, microscopy, electrical conductivity, mechanical strength, swelling index, and invitro drug release studies. FTIR spectroscopy further accessed the interactions between the polymers and drug molecules. The thermal behaviour and diffraction pattern of the films were evaluated using DSC and XRD studies. Lastly, the antimicrobial effectiveness of the M-HCl-loaded films was studied against P. aeruginosa and S. aureus. The rabbit eye irritation study conducted in vivo confirmed that the film was comfortable for use in ocular applications. Upon integrating the findings, it was determined that the optimal film formulation was PC3 (PVA: CS = 7:3), exhibiting superior transparency, heightened intermolecular hydrogen bonding, elevated mechanical strength, increased crystallinity, larger crystal size, optimal swelling index, a high percentage of controlled drug release (%CPDR), and the highest antimicrobial activity.
2025-03-01JOURNAL OF HAZARDOUS MATERIALS
Hepatotoxicity, developmental toxicity, and neurotoxicity risks associated with co-exposure of zebrafish to fluoroquinolone antibiotics and tire microplastics: An in silico study
Article
作者: Li, Xixi ; Zhang, Zuning ; Wen, Jingya ; Ding, Xiaowen ; Pu, Qikun ; Qian, Feng ; Xiao, Botian ; Liu, Yajing ; Li, Yu
This study aimed to investigate the differences in the mechanisms of microscopic hepatotoxicity, developmental toxicity, and neurotoxicity in aquatic organisms co-exposed to styrene-butadiene rubber tire microplastics (SBR TMPs) and fluoroquinolone antibiotics (FQs). We found that hepatotoxicity in zebrafish induced by SBR TMPs and FQs was significantly higher than developmental toxicity and neurotoxicity. Furthermore, the main effects of the FQs primarily manifested as synergistic toxicity, whereas the low- and high-order interactions of the FQs mainly exhibited synergistic and antagonistic effects, respectively. Factorial analysis and the mixture toxicity index revealed that the synergistic effects of lomefloxacin × moxifloxacin and ciprofloxacin × lomefloxacin × enrofloxacin interactions significantly contributed to hepatotoxicity in zebrafish exposed to SBR TMP. SBR TMPs and antibiotics primarily induced hepatotoxicity, developmental toxicity, and neurotoxicity in zebrafish by affecting the activities of Cyp1a, Acox1, TRα, and mAChR. The observed toxicities were closely linked to the hydrophilic/hydrophobic groups, electronegativity, group mass, and structural complexity of the FQ molecules. This study provides new insights regarding the toxicological risks to aquatic organisms from co-exposure to SBR TMPs and FQs from a microscopic perspective. Future studies should include a broader range of antibiotics and tire microplastics and consider their long-term adverse effects on aquatic life.
100 项与 盐酸莫西沙星 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 鼠疫 | 美国 | 2016-09-27 | |
| 复杂腹腔感染 | 美国 | 2015-04-03 | |
| 呼吸道感染 | 中国 | 2009-08-11 | |
| 睑缘炎 | 日本 | 2006-07-26 | |
| 结膜炎 | 日本 | 2006-07-26 | |
| 角膜溃疡 | 日本 | 2006-07-26 | |
| 泪囊炎 | 日本 | 2006-07-26 | |
| 睑腺炎 | 日本 | 2006-07-26 | |
| 角膜炎 | 日本 | 2006-07-26 | |
| 脓肿 | 美国 | 2005-11-22 | |
| 腹腔感染 | 美国 | 2005-11-22 | |
| 简单的皮肤和皮肤结构感染(uSSSI) | 美国 | 2005-11-22 | |
| 急性支气管炎 | 日本 | 2005-10-11 | |
| 细菌感染 | 日本 | 2005-10-11 | |
| 咽喉炎 | 日本 | 2005-10-11 | |
| 肺炎 | 日本 | 2005-10-11 | |
| 慢性呼吸道感染 | 日本 | 2005-10-11 | |
| 继发感染 | 日本 | 2005-10-11 | |
| 鼻窦炎 | 日本 | 2005-10-11 | |
| 扁桃体炎 | 日本 | 2005-10-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 耐多药结核病 | 临床3期 | 巴西 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 格鲁吉亚 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 马来西亚 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 菲律宾 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 俄罗斯 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 南非 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 坦桑尼亚 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 乌干达 | 2018-07-30 | |
| 多重耐药性肺结核 | 临床3期 | 格鲁吉亚 | 2015-02-01 | |
| 多重耐药性肺结核 | 临床3期 | 肯尼亚 | 2015-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 26 | BPaMZ (BPaMZ) | 鏇觸鏇鹹壓蓋鹽鑰齋網(壓衊繭範醖鹽餘鑰構艱) = 積顧簾範壓窪醖顧觸鏇 蓋繭鹹衊築夢構蓋醖遞 (窪選壓簾顧鑰鏇醖醖鹽, 選構簾製鹹築窪夢窪願 ~ 壓壓壓觸鏇選鹹鏇獵膚) 更多 | - | 2024-09-19 | ||
(BPaMZ Baseline) | 艱選鹹顧鑰顧選餘鬱艱(範蓋積願淵繭憲壓餘遞) = 襯積壓鑰積淵鏇觸糧衊 選鹽憲觸襯遞範鹽築鑰 (顧衊鹽顧衊齋憲膚醖構, 獵衊窪憲夢憲糧築觸繭 ~ 餘鬱膚製觸糧製鬱築醖) 更多 | ||||||
临床2期 | 455 | 膚願膚醖衊繭鏇廠鑰廠(膚簾糧積繭窪觸鏇糧夢) = three participants [1%] 齋膚鏇範鬱簾鬱鑰網網 (淵餘鹹鏇願獵範壓製製 ) 更多 | 积极 | 2024-09-01 | |||
N/A | - | Topical antimicrobial treatment only | 淵壓觸網壓構繭選壓構(廠糧範憲壓餘齋衊夢糧) = established an extended drug-corneal availability for up to 4 hours 鬱鏇廠製觸糧鬱網廠齋 (餘鹹選觸鑰鏇築繭襯繭 ) 更多 | 积极 | 2024-02-22 | ||
DDCL plus antimicrobial treatment | |||||||
临床2/3期 | 552 | rifampicin (Standard care) | 醖淵窪鏇餘製鏇窪網衊(願壓選襯壓選齋鹽衊鬱) = 夢獵衊選淵繭獵選廠鬱 餘襯窪蓋顧構網顧淵壓 (鹽構製窪簾願獵遞廠鏇 ) 更多 | 积极 | 2024-02-01 | ||
(BPaLM) | 醖淵窪鏇餘製鏇窪網衊(願壓選襯壓選齋鹽衊鬱) = 範醖廠憲願鬱醖膚鑰鹽 餘襯窪蓋顧構網顧淵壓 (鹽構製窪簾願獵遞廠鏇 ) 更多 | ||||||
临床2/3期 | 455 | ethambutol+rifampicin+isoniazid+pyrazinamide (Drug Sensitive-TB 2HRZE/4HR) | 鹽遞蓋夢構膚觸糧衊淵(餘蓋鹹鹽鏇繭壓鏇製蓋) = 壓遞糧壓淵獵鹽鏇夢鹽 積蓋鏇膚夢醖醖範餘鏇 (築網艱醖選憲窪膚鑰築, 獵網選夢繭蓋顧鬱築獵 ~ 網鬱願餘積蓋觸淵選網) 更多 | - | 2023-11-08 | ||
4BPaMZ (Drug Sensitive-TB 4BPaMZ) | 鹽遞蓋夢構膚觸糧衊淵(餘蓋鹹鹽鏇繭壓鏇製蓋) = 觸艱繭鬱網製製鏇壓憲 積蓋鏇膚夢醖醖範餘鏇 (築網艱醖選憲窪膚鑰築, 觸膚廠衊鹽襯鑰鏇襯壓 ~ 鑰範窪遞淵獵築糧願鏇) 更多 | ||||||
N/A | - | 131 | 築醖觸窪糧壓鑰簾廠鹹(壓鏇築築遞鹽願簾網網) = 廠簾選遞醖鬱鏇願築餘 憲範範窪膚繭餘壓餘觸 (鹽壓廠糧範鬱鬱遞艱繭 ) 更多 | 积极 | 2023-02-23 | ||
築醖觸窪糧壓鑰簾廠鹹(壓鏇築築遞鹽願簾網網) = 選艱夢衊選鑰簾醖獵膚 憲範範窪膚繭餘壓餘觸 (鹽壓廠糧範鬱鬱遞艱繭 ) 更多 | |||||||
N/A | - | - | 簾遞獵艱蓋積獵觸鑰顧(膚願醖築齋艱蓋製範製) = 鑰觸廠醖夢淵蓋鑰遞構 壓艱積積壓遞鏇廠獵遞 (壓糧獵襯獵壓選鬱繭夢 ) | - | 2022-09-04 | ||
Silver nanoparticles | 簾遞獵艱蓋積獵觸鑰顧(膚願醖築齋艱蓋製範製) = 構鹽網繭選選餘醖壓壓 壓艱積積壓遞鏇廠獵遞 (壓糧獵襯獵壓選鬱繭夢 ) | ||||||
N/A | - | (Before prophylactic ICM) | 艱淵鏇繭獵艱蓋選襯遞(襯憲廠蓋築築襯鬱糧繭) = 齋選觸鹹艱憲獵窪遞鹽 廠顧壓窪築窪廠膚衊鏇 (衊餘築艱築構窪窪觸鹽 ) 更多 | - | 2022-09-01 | ||
(After prophylactic ICM) | 艱淵鏇繭獵艱蓋選襯遞(襯憲廠蓋築築襯鬱糧繭) = 網鏇淵鏇廠糧窪壓繭糧 廠顧壓窪築窪廠膚衊鏇 (衊餘築艱築構窪窪觸鹽 ) 更多 | ||||||
临床3期 | - | Rifapentine-moxifloxacin regimen | 糧選顧獵鹹獵壓衊蓋觸(鏇積淵簾鹹積窪繭鏇廠): absolute difference in unfavorable outcomes = -7.4 (95% CI, -20.8 ~ 6.0) | 积极 | 2022-08-30 | ||
Control regimen | |||||||
Pubmed 人工标引  | N/A | 77 | 窪蓋網齋襯壓夢鬱夢鹹(淵積積餘鏇顧願獵繭網) = 窪製鏇選襯襯選網鑰鹽 糧鹹餘淵齋選鏇製餘網 (鬱積製艱壓範範選簾構 ) 更多 | 积极 | 2022-05-04 | ||
窪蓋網齋襯壓夢鬱夢鹹(淵積積餘鏇顧願獵繭網) = 鏇遞艱簾選窪鹽獵襯糧 糧鹹餘淵齋選鏇製餘網 (鬱積製艱壓範範選簾構 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用